Page 17 - Delaware Medical Journal - December 2016
P. 17
SCIENTIFIC ARTICLE
and IV was calculated on the basis of
diagnostic thyroid surgery.
RESULTS
for surgeon performed, ultrasound guided Figure 2). (instead of diagnostic surgery or repeat males. One patient (4 percent), a Bethesda This patient elected diagnostic thyroid variant of papillary thyroid cancer patients had a result from ThyroSeq either with one or more mutations or with no
no mutation (13 patients Bethesda III and
(100 percent) patients with no mutation elected active surveillance instead of followed clinically and with ultrasound at six to 12 month intervals. The mean age of patients with no mutation was 57.3 years. size of the nodules without a mutation none of the patients with no mutation have undergone surgery and all (100 percent) have been under close clinical observation with ultrasound every six to 12 months for
mutation, followed with ultrasound thus far have increased in size, had a change
in ultrasound characteristics of the nodule, or developed cervical adenopathy; and Assuming all un-operated nodules are truly benign and remain benign, the study period.
for a mutation (Table 1) and went on to surgery. The mean age was 49.9 years. female and one of eight (12 percent) were male. The mean size of the nodule with a
All four (100 percent) patients were female. The mean size of the nodule was 21 mm
mutated patients and both were positive for papillary thyroid carcinoma (PTC) on
with RAS mutation were benign on Table 1). One patient
TABLE I: Mutations detected on ThyroSeq testing and final pathology
TEST
AUS/FLUS
FN
FN
BRAF V600 E
Papillary Thyroid Cancer
FLUS
BRAF V600 E
Papillary Thyroid Cancer
FN
Met Gene
Benign adenomatoid nodule
FLUS
PAX8/PPARg
Benign adenomatoid nodule
FN
HRAS
Follicular Neoplasm
FLUS
HRAS
Follicular Neoplasm
FLUS
KRAS
Follicular Variant of Papillary Thyroid Cancer
FN
NRAS +P 53
Follicular Variant of Papillary Thyroid Cancer
FN
NRAS
Follicular Neoplasmv
Del Med J | December 2016 | Vol. 88 | No. 12
369
